CGS-15943

CGS-15943
Clinical data

ATC code	none
Legal status
Legal status	Uncontrolled
Identifiers
IUPAC name 9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
CAS Number	104615-18-1^N
PubChem CID	2690
IUPHAR/BPS	384
ChemSpider	2589^Y
ChEBI	CHEBI:131351^N
ChEMBL	CHEMBL16687^Y
Chemical and physical data
Formula	C₁₃H₈ClN₅O
Molar mass	285.689 g/mol
3D model (Jmol)	Interactive image
SMILES ClC1=CC=C2N=C(N)N3N=C(C4=CC=CO4)N=C3C2=C1
InChI InChI=1S/C13H8ClN5O/c14-7-3-4-9-8(6-7)12-17-11(10-2-1-5-20-10)18-19(12)13(15)16-9/h1-6H,(H2,15,16)^Y Key:MSJODEOZODDVGW-UHFFFAOYSA-N^Y
^NY (what is this?)

CGS-15943 is a drug which acts as a potent and reasonably selective antagonist for the adenosine receptors A₁ and A_2A, having a K_i of 3.3nM at A_2A and 21nM at A₁. It was one of the first adenosine receptor antagonists discovered that is not a xanthine derivative, instead being a triazoloquinazoline. Consequently, CGS-15943 has the advantage over most xanthine derivatives that it is not a phosphodiesterase inhibitor, and so has more a specific pharmacological effects profile. It produces similar effects to caffeine in animal studies, though with higher potency.

...
Wikipedia